Egetis Therapeutics (EGTX) Q1 2025 earnings summary

Executive summary

• Achieved full European Commission approval for Emcitate in February 2025 as the first and only treatment for MCT8 deficiency, marking a transition to a commercial-stage rare disease company.

• First commercial launch in Germany set for May 1, 2025, with pricing and reimbursement processes initiated in major EU countries.

• U.S. pivotal ReTRIACt study progressing, with NDA submission planned for 2025 and anticipated U.S. launch in 2026.

• Expansion into Middle East, North Africa, Turkey, and Japan through partnerships and ongoing regulatory discussions, leveraging new PMDA guidelines for potential trial exemption.

• ETA guidelines now recommend Emcitate for all MCT8 deficiency patients, supporting market access and awareness.

Financial highlights

• Q1 2025 revenues reached SEK 12.7 million, up from SEK 12.1 million year-over-year, mainly from Emcitate's Managed Access Program.

• Gross profit margin lower due to non-recurring milestone payments and new intangible R&D depreciations triggered by EU approval.

• Q1 2025 post-tax result was minus SEK 62.9 million, improved from minus SEK 75 million year-over-year, mainly due to finance line items.

• Cash position at end of March 2025 was SEK 273 million, up from SEK 252 million year-over-year.

• Operating cash flow for Q1 2025 was SEK -66.1 million versus SEK -55.4 million last year, mainly due to working capital changes.

Outlook and guidance

• U.S. NDA submission for Emcitate expected in 2025, with approval and launch targeted for 2026.

• Continued focus on expanding Emcitate access globally, including ongoing regulatory and commercial preparations in the U.S., EU, Japan, and partnerships in Middle East, North Africa, and Turkey.

• 2025 priorities include optimizing EU pricing/reimbursement, completing ReTRIACt study, and preparing for U.S. launch.